Exec dir Ziv Gan-Or spoke at IRBD StudyGroup's annual meeting, discussing the importance of using human-derived data and models in identifying and testing new treatments for #RBD, #Parkinsons, dementia. He also shared his lab’s latest findings of potential genes + biological pathways involved in RBD
@theneuro.bsky.social @healthsciences.mcgill.ca @cusm-muhc.bsky.social @spcanadaofficielle.bsky.social
Tour d'horizon de la #rechercheclinique sur la #SP avec le Dr Adil Harroud, clinicien-chercheur au #Neuro. De nouvelles études en cours visent à gérer la progression de la maladie et des symptômes difficiles de façon plus précise et efficace. Lire l'entrevue: cru.mcgill.ca/fr/avancees-...
@theneuro.bsky.social @cusm-muhc.bsky.social @mscanadaofficial.bsky.social @spcanadaofficielle.bsky.social
🔬Plusieurs nouveaux essais cliniques visant à ralentir la progression de la #SP débuteront bientôt au NeuroCRU.
🩺Several new studies aiming to slow the progression of #MS starting soon at Neuro CRU.
📩Info: cru.mcgill.ca/ms or ms-cru.neuro@mcgill.ca.
@theneuro.bsky.social @healthsciences.mcgill.ca @cusm-muhc.bsky.social @douglasresearch.bsky.social
Cyrena Gerardi, gestionnaire des opérations à l'URC et Dr Simon Ducharme, chercheur principal, ont assisté au Forum Recherche clinique présenté par @Catalisquebec. Une journée réunissant chercheurs et dirigeants de l'écosystème des sciences de la vie pour faire avancer la #rechercheclinique au #QC.
@theneuro.bsky.social
@healthsciences.mcgill.ca
@cusm-muhc.bsky.social
#EARTHDAY: The Neuro’s #GreenLabs have made huge strides in reducing research-related plastic waste: 180,000 cu. ft. of expired lab material were diverted to nursing schools in Montreal and 2000 lbs. of ice packs were repurposed by community organizations to help fight food insecurity. #mcgill
Ziv Gan-Or, executive director of the Clinical Research Unit at The Neuro and the GBA1-Can Initiative speaks eSleep Europe virtual congress 2025.
NeuroCRU exec dir @zivganor.bsky.social
gave a keynote talk at #SleepEurope virtual congress discussing his lab’s work on the genetics of REM Sleep Behavior Disorder #RBD, allowing researchers to find #genetic targets like #GBA1 for #drugdevelopment and to identify patients best suited to trials.
@parkinsonseurope.bsky.social @parkinsons.org.uk @parkinsoncanada.bsky.social @parkinsondotorg.bsky.social
Neuro CRU's Ziv Gan-Or leads the GBA1-Canada initiative, an open science platform dedicated to advancing research and treatment for #Parkinsons due to mutations in the #GBA1 gene. GBA1-CAN international conference: June 5-7. Deadline for abstracts: March 31. Register: lnkd.in/eNbQBhvW
L’analyse a révélé que les critères de socialisation, notamment la réciprocité émotionnelle, la communication non verbale et l’établissement de relations, ne jouent pas un rôle déterminant dans le diagnostic d’autisme.
Une analyse de l'IA a révélé que les critères de socialisation, notamment la réciprocité émotionnelle, la communication non verbale et l’établissement de relations, ne jouent pas un rôle déterminant dans le diagnostic d’autisme.
www.mcgill.ca/neuro/fr/cha...
A partnership between @zivganor.bsky.social at The Neuro and Martine Tétreault at @umontreal.ca received $7 million from @genomecanada.bsky.social Canada to build a comprehensive resource of genetic and clinical diversity of neurological disorders in Quebec.
bsky.app/profile/then...
@theneuro.bsky.social @cusm-muhc.bsky.social @rimuhc.bsky.social
If you can use a smartphone, you could help move #Parkinsons research forward! Healthy participants over 60 are needed to test a smartphone app that aims to detect subtle changes in movement and better track the progression of the disease. For info: cru.mcgill.ca/mvtdisorders (514) 398-5500.
Our congratulations to Dr. Ron Postuma and Dr. Angela Genge. These world-leading clinician-researchers and principal investigators at NeuroCRU were recognized with the King Charles III Coronation Medal for their contributions to advances in the development of treatment and patient care in neurology.
@theneuro.bsky.social, @healthsciences.mcgill.ca, @cusm-muhc.bsky.social, @rimuhc.bsky.social, @sla
Grande nouvelle! Des recherches cliniques menées au Neuro ont permis de valider une thérapie révolutionnaire qui peut ralentir la progression de la #SLA de type #SOD1. #SantéCanada a accordé une approbation conditionnelle au #Tofersen maintenant appelé #Qalsody. Entrevue: bit.ly/qalsodyurc
@theneuro.bsky.social @healthsciences.mcgill.ca @cusm-muhc.bsky.social
*This* is why clinical research is vital! A trial run at the CRU led to a breakthrough therapy that allows individuals with #SOD1 #ALS to stabilize their disease and even regain function. #Qalsody has now received conditional approval from Health Canada. #raredisease #tofersen
bit.ly/qalsodyhcan
@hdbuzzfeed.bsky.social @theneuro.bsky.social @huntingtonsc.bsky.social @healthsciences.mcgill.ca
A new non-interventional study aims to identify the most common genetic variations of #HuntingtonsDisease to help researchers develop more targeted treatments. This international #clinicaltrial is at 4 sites in Canada, including NeuroCRU. Info: neurocog-cru.neuro@mcgill.ca. cru.mcgill.ca
Ziv Gan-Or, executive director of the Clinical Research Unit at The Neuro, presents his lab's work on the GBA1 mutation, responsible for a rare form of Parkinson's Disease during the 6th international Congress on Rare Diseases in Vienna. #Rare2025
CRU exec director @ZivGanOr was in Vienna for #RARE2025 to discuss his lab’s work understanding #GBA1, a genetic mutation behind a rare subtype of #Parkinsons. The CRU works to offer the most advanced investigational therapies for individuals with rare diseases, including RNA and #genetherapy.
Les maladies rares neurologiques sont surreprésentées au Québec et les traitements potentiels sont souvent inexistants. La recherche est essentielle. L’Unité de recherche clinique du Neuro élargit la liste des conditions rares couvertes par ses essais cliniques. Études: cru.mcgill.ca/fr/essais.
